Stock Analiz

Bio-rad Laboratories, Inc. (BIO) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Bio-rad Laboratories’s revenue went from $2.1B in fiscal 2016 to $2.6B in fiscal 2025, growth of about 2.5% a year.

Net income in fiscal 2025 was $760M, a net margin of 29.4%; the best year in this period was 2021 with $4.3B.

Over the twelve months to September 30, 2026, revenue was $2.6B and net income $1.0B.

Free cash flow was $375M in fiscal 2025 and positive in 9 of the 10 years shown.

The diluted share count fell 8% over the period (buybacks).

Revenue, profit and cash flow by year

Revenue
2016: $2.1B162017: $2.2B172018: $2.3B182019: $2.3B192020: $2.5B202021: $2.9B212022: $2.8B222023: $2.7B232024: $2.6B242025: $2.6B25$2.6B
Net income
2016: $26M162017: $122M172018: $366M182019: $1.8B192020: $3.8B202021: $4.3B212022: -$3.6B222023: -$637M232024: -$1.8B242025: $760M25$760M
Free cash flow
2016: $75M162017: -$7M172018: $156M182019: $359M192020: $476M202021: $536M212022: $82M222023: $218M232024: $290M242025: $375M25$375M
EPS (diluted)
2016: $0.88162017: $4.07172018: $12.10182019: $58.27192020: $126.47202021: $140.83212022: $-121.79222023: $-21.82232024: $-65.36242025: $27.8525$27.85

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$2.6B$2.6B$2.6B$2.7B$2.8B$2.9B$2.5B$2.3B$2.3B$2.2B$2.1B
Gross profit$1.3B$1.3B$1.4B$1.4B$1.6B$1.6B$1.4B$1.3B$1.2B$1.2B$1.1B
Operating income-$62M$47M$269M$338M$483M$500M$421M$230M-$103M$119M$56M
Net income$1.0B$760M-$1.8B-$637M-$3.6B$4.3B$3.8B$1.8B$366M$122M$26M
EPS (diluted)$37.71$27.85$-65.36$-21.82$-121.79$140.83$126.47$58.27$12.10$4.07$0.88
R&D$266M$276M$296M$247M$257M$261M$218M$203M$199M$250M$206M
Revenue growth—+0.7%−3.9%−4.7%−4.1%+14.8%+10.1%+1.0%+6.0%+4.5%+2.4%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$468M$532M$455M$375M$194M$669M$585M$458M$285M$104M$216M
Capital spending-$139M-$158M-$166M-$157M-$113M-$134M-$109M-$99M-$130M-$111M-$141M
Free cash flow$329M$375M$290M$218M$82M$536M$476M$359M$156M-$7M$75M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks$79M$296M$204M$429M$216M$50M$100M$28M$49M$3M$0
Stock-based pay$61M$58M$62M$61M$61M$51M$42M$36M$28M$23M$20M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$1.5B$1.7B$1.6B$1.8B$870M$991M$1.1B$845M$755M$839M
Debt—$1.4B$1.4B$1.4B$1.4B$223M$224M$225M$439M$435M$434M
Equity—$7.5B$6.6B$8.7B$9.6B$13.7B$9.9B$5.8B$4.0B$2.9B$2.6B
Total assets—$10.6B$9.4B$12.3B$13.5B$17.8B$13.0B$8.0B$5.6B$4.3B$3.9B
Shares (diluted)27M27M28M29M30M30M30M30M30M30M30M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin51.3%51.9%53.7%53.4%55.9%56.0%56.5%54.4%53.4%55.0%55.0%
Operating margin-2.4%1.8%10.5%12.7%17.2%17.1%16.6%9.9%-4.5%5.5%2.7%
Net margin39.5%29.4%-71.9%-23.9%-129.4%145.6%149.8%76.1%16.0%5.7%1.3%
FCF margin12.7%14.5%11.3%8.2%2.9%18.3%18.7%15.6%6.8%-0.3%3.6%
ROIC—0.4%2.7%2.5%3.4%2.8%3.2%3.0%-1.7%2.8%1.2%
ROE—10.2%-28.1%-7.3%-37.7%31.1%38.6%30.6%9.1%4.2%1.0%

Frequently asked questions

What is Bio-rad Laboratories’s annual revenue?

$2.6B in fiscal 2025 and $2.6B over the twelve months to September 30, 2026.

How much profit does Bio-rad Laboratories make?

Net income was $760M in fiscal 2025 (net margin 29.4%).

Is Bio-rad Laboratories’s revenue growing?

Yes: revenue rose 0.7% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.